Prazosin plasma concentration and blood pressure reduction. 1982

P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong

Prazosin was administered to 16 patients with essential hypertension in an initial dose of 0.5 mg, after which the blood pressure (BP), pulse, and plasma concentrations of prazosin were measured at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 hours. The dose of prazosin was then increased over 16 to 20 weeks, and similar sequences of measurements were obtained twice. Eleven patients completed the 20-week course. All patients did not respond in a similar way; two distinct patterns of BP and pulse response emerged, although there was no significant difference in the pharmacokinetic parameters, namely, absorption rate constant (Ka), maximum plasma concentration (Cpmax), time to reach the maximum concentration (Tmax), prazosin plasma half-life (T 1/2), elimination rate constant (kel), prazosin plasma concentration-time curve (AUC), and clearance. Patients in Group 1 had a marked reduction (52/30 mm Hg) of BP after the first dose of prazosin, no pulse increase, and needed a small dose of prazosin to maintain an adequate BP response. Patients in Group 3 had a minimal reduction in BP (14/13 mm Hg) after a first dose, a significant pulse increase, and needed a high dose of prazosin to control their BP. We conclude that this effect might be due to a different drug-receptor interaction, and the BP response and dose could be predicted from the response of the first dose of prazosin.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011187 Posture The position or physical attitude of the body. Postures
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance

Related Publications

P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
July 1979, Journal of clinical pharmacology,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
February 1976, British journal of clinical pharmacology,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
January 1997, Acta cardiologica,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
December 1978, Clinical science and molecular medicine. Supplement,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
October 1981, Clinical pharmacology and therapeutics,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
January 1983, Therapeutic drug monitoring,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
January 1984, The American journal of cardiology,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
January 1982, Journal of cardiovascular pharmacology,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
August 1977, The Medical journal of Australia,
P Larochelle, and P du Souich, and P Hamet, and P Larocque, and J Armstrong
December 1981, Clinical science (London, England : 1979),
Copied contents to your clipboard!